Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization - Total (2022 - 2025)

InMed Pharmaceuticals' Depreciation & Amortization - Total history spans 4 years, with the latest figure at $12206.0 for Q2 2025.

  • For Q2 2025, Depreciation & Amortization - Total rose 124.37% year-over-year to $12206.0; the TTM value through Dec 2025 reached $24409.0, down 46.3%, while the annual FY2025 figure was $50204.0, 5.16% up from the prior year.
  • Depreciation & Amortization - Total reached $12206.0 in Q2 2025 per INM's latest filing, roughly flat from $12203.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $14242.0 in Q4 2023 to a low of $5440.0 in Q2 2024.
  • Average Depreciation & Amortization - Total over 4 years is $11773.0, with a median of $12209.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization - Total: crashed 57.88% in 2024, then skyrocketed 124.37% in 2025.
  • A 4-year view of Depreciation & Amortization - Total shows it stood at $8056.0 in 2022, then soared by 76.79% to $14242.0 in 2023, then fell by 14.27% to $12209.0 in 2024, then fell by 0.02% to $12206.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Depreciation & Amortization - Total are $12206.0 (Q2 2025), $12203.0 (Q1 2025), and $12209.0 (Q4 2024).